secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001140361-25-004957
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GNI Group FY2024 revenue down 9.2%, operating profit plunges 89.3%; Gyre pipeline catalysts set for 2025
--------------------------------------------------------------------------------

- Revenue ¥23,611M (-9.2% YoY); operating profit ¥1,402M (-89.3%); pre-tax profit ¥238M (-98.1%).
- Net loss attributable to owners of parent ¥977M (vs. ¥8,094M profit in FY2023); basic EPS ¥19.55 (vs. ¥169.50).
- Operating cash flow negative ¥3,164M; investing cash outflow ¥10,361M; cash position ¥10,115M.
- Gyre Pharms: Hydronidone Phase 3 topline data expected Q1 2025; F573 Ph2 completion, F230 Ph1 start planned.
- F528 IND submission targeted for Dec 2025; GNI Group forecasts FY2025 revenue ¥28,733M (+21.7% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/0001140361-25-004957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-004957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer